Pegvisomant: An advance in clinical efficacy in acromegaly

European Journal of Endocrinology, Supplement

Volumn 148, Issue 2, 2003, Pages

  Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PEGVISOMANT; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ARTHRALGIA; ASTHENIA; BACKACHE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DIARRHEA; DIMERIZATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INHIBITION KINETICS; INJECTION SITE; INJURY; LONG TERM CARE; PAIN; PARESTHESIA; PREMATURITY; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT INFECTION; SINUSITIS; SLEEP APNEA SYNDROME; SURVIVAL RATE; SWEATING; TACHYPHYLAXIS; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ADENOMA; ADULT; AGED; BLOOD GLUCOSE; CLINICAL TRIALS; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RECEPTORS, SOMATOTROPIN;

EID: 0037696193     PISSN: 08044635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Stewart PM. Current therapy for acromegaly. Trends in Endocrinology and Metabolism 2000 11 128-132.
2. Melmed S, Jackson I, Kleinberg D & Klibanski A. Current treatment guidelines for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 2646-2652.
3. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K et al. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529.
4. Bates AS, Van't Hoff W, Jones JM & Clayton RN. An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine 1993 86 293-299.
5. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3419-3426.
6. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ & Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology 1994 41 95-102.
7. Orme SM, McNally RJ, Cartwright RA & Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734.
8. Jenkins D, O'Brien I, Johnson A, Shakespear R, Sheppard MC & Stewart PM. The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clinical Endocrinology 1995 43 517-522.
9. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR & Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clinical Endocrinology 1998 49 653-657.
10. Ross DA & Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. Journal of Neurosurgery 1988 68 854-867.
11. Osman IA, James RA, Chatterjee S, Mathias D & Kendall-Taylor P. Factors determining the long-term outcome of surgery for acromegaly. Quarterly Journal of Medicine 1994 87 617-623.
12. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB & Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocrinology 1999 50 561-567.
13. Gittoes NJ, Sheppard MC, Johnson AP & Stewart PM. Outcome of surgery for acromegaly - the experience of a dedicated pituitary surgeon. Quarterly Journal of Medicine 1999 92 741-745.
14. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F et al. Effect of different dopaminergic agents in the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 518-523.
15. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism 1998 83 374-378.
16. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Annals of Internal Medicine 1992 117 711-718.
17. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1995 80 2768-2775.
18. Vance ML & Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Archives of Internal Medicine 1991 151 1573-1578.
19. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C et al. Sandostatin LAR in acromegalic patients: long-term treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 23-28.
20. Turner RE, Lindsell DR, Vadivale A, Thillainayagam AV & Wass JA. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly. European Journal of Endocrinology 1999 141 590-594.
21. Kopchick JJ. Discovery and mechanism of action of pegvisomant. European Journal of Endocrinology 2003 148 (Suppl 2) S21-S25.
22. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
23. van der Lely AJ, Hutson R, Trainer PJ, Besser GM, Barkan A, Katznelson L et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.